Phibro (PAHC) Q4 2026 Earnings Call Transcript
Phibro (PAHC) reported Q4 2026 net sales of $396.7M, up 5%, and adjusted EBITDA of $255M, up 39% YoY. Full-year sales reached $1.518B, up 17%, with adjusted EBITDA up 39%. CEO Dani Bendheim highlighted strong performance across segments, including a 20% increase in Mineral Nutrition sales. The company provided fiscal 2027 guidance, expecting net sales of $1.55B-$1.6B and adjusted EBITDA of $258M-$268M. Phibro also announced the closure of a Chicago facility and discussed regulatory uncertainties
How this was made
The 30-second read
Why it matters
Earnings beat and forward guidance provide a clear catalyst for short-term price moves and longer-term valuation adjustments.
Market read
Strong FY results and optimistic FY 2027 outlook make PAHC a notable trade idea in the agribusiness sector.
What to watch
Closure of the Chicago Heights plant could temporarily disrupt supply and affect short-term earnings.
Background
Phibro (PAHC) completed its FY 2026 earnings call, highlighting record sales and integration progress of recent acquisitions.
Ticker impact
Phibro reported FY 2026 results with record $1.5B sales, 39% EBITDA growth and provided FY 2027 guidance.
Potential price appreciation on the back of earnings beat and guidance raise.
Revenue and EBITDA beat expectations; guidance above prior outlook; market likely to price in growth.
Market effects
Animal health and mineral nutrition segments show strong growth, supporting sector momentum.
Positive outlook may boost related agribusiness stocks in North America.
Regulatory uncertainty in Brazil could affect other animal health exporters.
Counterpoint
If virginiamycin regulatory approval stalls, guidance may be overly optimistic.
Key entities
- ExecutiveDani Bendheim
President and CEO delivering earnings commentary.
- ExecutiveGlenn David
Co-presenter of the earnings call.
